Bionomics Ltd – ADR (NASDAQ:BNOX) shares are trading higher by 177% to 53 cents Tuesday morning after the company announced it received a milestone payment of AUD$1 million from Carina Biotech related to their partnered oncology program, BNC101. What To Know: This payment aligns with their 2020 exclusive license agreement for BNC101, a monoclonal antibody targeting LGR5, a cancer stem cell antigen. Carina Biotech is developing an LGR5-targeted CAR-T therapy, CNA3103, for metastatic colorectal cancer, and Bionomics could earn up to AUD$118 million in further development, regulatory and commerci…